https://pipelinereview.com/chugai-obtains-approval-of-humanized-anti-pd-l1-monoclonal-antibody-tecentriq-intravenous-infusion-1200mg-for-the-treatment-of-unresectable-advanced-or-recurrent-non-small-cell-lung-cancer/